NULISA™ Multiplex Assays - Biognosys

Services

NULISA™ Multiplex Assays

Unlock the full potential of your protein biomarker studies with NULISA™ technology

Through our collaboration with Alamar Biosciences, Biognosys is the provider of choice for NULISAseq™ multiplex assay services tailored for biopharma research. These services are offered from our state-of-the-art facility in Switzerland, equipped with the ARGO™ HT System. These panels are designed for high-sensitivity, multiplexed analysis of plasma and other biofluids, enabling deep insights into complex biological processes and proteins.

    By selecting any or all of the topic preferences below, you agree to receive respective information from Biognosys via email. You can unsubscribe from these communications at any time. By submitting this form, you confirm that you consent to Biognosys processing of your personal data for the purposes and in the manner as described in our Privacy Notice.

      By selecting any or all of the topic preferences below, you agree to receive respective information from Biognosys via email. You can unsubscribe from these communications at any time. By submitting this form, you confirm that you consent to Biognosys processing of your personal data for the purposes and in the manner as described in our Privacy Notice.

      Description

      NULISA™ leverages a proprietary sequential immunocomplex capture and release mechanism, combined with advanced Next-Generation Sequencing (NGS), to achieve ultra-high sensitivity and scalable multiplexing. NULISAseq panels enable the detection of previously hard-to-measure biomarkers using just 50 μl of plasma or biofluid, offering exceptional sensitivity and specificity. Additionally, the platform supports advanced biomarker discovery with an option for GCP-compliant and GLP-like lab operations, making it ideal for exploratory profiling of clinical trial samples.

      NULISAseq™ CNS Disease and Inflammation Panels

      Assays for Immunology

      NULISAseq Inflammation Panel 250

      Deepest profiling of inflammatory response:

      VIEW TARGET LIST

       

      NULISAseq™ Inflammation Panel AQ

      Quantitate more biomarkers in clinical cohort studies:

      VIEW TARGET LIST

       

      NULISAseq™ Mouse Panel 120
      Most comprehensive coverage of protein expression in murine models:

      VIEW TARGET LIST

       

      NULISAqpcr™ Single-Plex Assays

      Ultra-high sensitivity measurement of your most informative biomarkers.
      Detect important low abundance proteins with attomolar sensitivity (low fg/mL):

      VIEW TARGET LIST

       

      Note: Some targets may be subject to change due to ongoing technological advancements. For the most up-to-date target list, please consult with our experts.

      Assays for Neurology

      NULISAseq™ CNS Disease Panel 120

      Sensitivity meets specificity. One powerful panel for comprehensive neurodegenerative research:

      VIEW TARGET LIST

       

      NULISAseq™ Mouse Panel 120

      Most comprehensive coverage of protein expression in murine models:

      VIEW TARGET LIST

       

      NULISAqpcr™ Single-Plex Assays

      Ultra-high sensitivity measurement of your most informative biomarkers.
      Detect important low abundance proteins with attomolar sensitivity (low fg/mL):

      VIEW TARGET LIST

       

      Resources

      Filter By

      Comprehensive Plasma Proteomics by Biognosys

      The NULISA affinity-based assays can be combined with Biognosys’ TrueDiscovery mass spectrometry-based services powered by the P2 Enrichment System to achieve the most comprehensive plasma proteome profiling in your research.

       

      Sample requirements

      NULISAseq™ assays require 50 μl of plasma or other biofluid.

      Project management

      Biognosys is committed to providing the best possible results to our customers at the fastest possible project turnaround time.

       

      WORKING WITH US

      Contact